Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Mirecule Inc. is currently prosecuting patent applications in the Biotechnology & Pharmaceuticals technology area. The portfolio features 1 pending office action, suggesting a focused stage of examination for its biotech or pharmaceutical innovations. This single action indicates that the company is currently prioritizing a specific technological advancement within the Biotechnology & Pharmaceuticals field.
The prosecution process is streamlined through 1 distinct examiner and 1 distinct art unit. Having 1 distinct examiner means that the company's legal representatives are interacting with a single individual at the USPTO, which can lead to a more consistent and predictable dialogue. The 1 distinct art unit involved further narrows the technical scope of the examination, ensuring that the 1 pending office action is reviewed by a specialized group.
CHONG, KIMBERLY is the busiest examiner for Mirecule Inc., with 1 busiest examiner pending office action currently under review. This 1 action is the only pending matter in the portfolio, making CHONG, KIMBERLY the primary figure in the company's current patent office interactions. Success for this portfolio depends on effectively addressing the specific feedback provided by CHONG, KIMBERLY in this 1 busiest examiner pending office action.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHONG, KIMBERLY | 1 | 72.4% | +13.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18455756 | TARGETED INHIBITION USING ENGINEERED OLIGONUCLEOTIDES | CHONG, KIMBERLY | — |
| Art Unit | Apps |
|---|---|
| 1636 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18455756 | TARGETED INHIBITION USING ENGINEERED OLIGONUCLEOTIDES | CHONG, KIMBERLY | 1636 | §102§103§112DP | Non-Final OA | — | Pending | Aug 25, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial